Clinical Trials

790 enrolled

Lymphoma, Follicular

NCT06765317 2026-06-05

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07278856 2026-06-05

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Phase 1 Recruiting

20 enrolled

Lymphoma, T-Cell

NCT01868451 2026-06-04

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Phase NA Completed

118 enrolled

Hodgkin Disease

NCT04850495 2026-06-04

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1 Suspended

38 enrolled

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02112916 2026-06-03

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

847 enrolled 19 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06124157 2026-06-03

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Burkitt Lymphoma

NCT06317662 2026-06-03

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Phase 2/3 Active not recruiting

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT01046825 2026-06-02

Mature B-Cell Lymphoma And Leukemia Study III

128 enrolled 12 charts

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT02883049 2026-06-02

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Phase 3 Completed

5,949 enrolled 28 charts

Burkitt Lymphoma

NCT03150693 2026-06-02

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

310 enrolled

Phase 1/2 Active not recruiting

Burkitt Lymphoma

NCT04542824 2026-06-02

EPCORE™ NHL-3

78 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-06-02

EPCORE™ CLL-1

194 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-06-02

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04685616 2026-06-02

RADAR

1,042 enrolled

Hodgkin Disease

NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2 Suspended

170 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-06-02

EPCORE™FL-2

1,095 enrolled

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 1 FDA

Phase EARLY_PHASE1 Recruiting

Hodgkin Disease

NCT04139304 2026-06-01

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

15 enrolled

Plasmablastic Lymphoma

NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1 Recruiting

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT00792948 2026-05-29

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

97 enrolled 7 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03269669 2026-05-29

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Follicular

NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

363 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06717347 2026-05-29

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-29

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01190930 2026-05-28

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Phase 3 Completed

9,350 enrolled 51 charts

Phase 3 Active not recruiting

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

30 enrolled

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Phase 2 Completed

30 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01476410 2026-05-22

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Phase 2 Completed

49 enrolled 25 charts

Hodgkin Disease

NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular

NCT07551583 2026-05-20

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

15 enrolled

Hodgkin Disease

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT06091254 2026-05-19

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06091865 2026-05-15

OLYMPIA-3

904 enrolled

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

20 enrolled